Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus

► ASP2151 is a helicase-primase inhibitor against Alphaherpesvirinae viruses. ► Combination effect of ASP2151 with existing antiherpes agents was studied. ► ASP2151 combined with ACV showed synergistic effect against HSV-1, HSV-2, and VZV. ► ASP2151 combined with VACV was more potent than each monotherapy in mouse model.